Objectives/Hypothesis: Hearing loss and enlarged vestibular aqueduct (EVA) can be inherited as an autosomal recessive trait caused by mutant alleles of the SLC26A4 gene. In some other families, EVA does not segregate in a typical autosomal recessive pattern. The goal of this study was to characterize the SLC26A4 genotypes and phenotypes of extended families with atypical segregation of EVA.
INTRODUCTION
Enlarged vestibular aqueduct (EVA) is the most common malformation observed in imaging studies of temporal bones of children with sensorineural hearing loss. 1 EVA was originally defined as a diameter >1.5 mm at the midpoint of the vestibular aqueduct, 2 but recent studies have shown that a midpoint diameter >1.0 mm is specifically associated with hearing loss. 3 The hearing loss associated with EVA can have a pre-, peri-or even postlingual onset and can affect one or both ears. 4 In patients with bilateral EVA, the hearing loss is usually asymmetric. A distinctive clinical feature of EVA is sudden loss or fluctuation in hearing. In some EVA ears, sudden loss or fluctuation can be precipitated by minor head trauma or barotrauma.
Mutations of the SLC26A4 gene are one etiology of EVA. SLC26A4, which is located on chromosome 7, was initially discovered as the gene underlying Pendred syndrome, 5 an autosomal recessive disorder originally described as the combination of congenital deafness and thyroid goiter. 6 Numerous studies have further elucidated the auditory and thyroid phenotypic spectrum associated with SLC26A4 mutations. Ultrasonography is a noninvasive and quantitative method to detect the abnormalities of texture (e.g., nodules) and volume in Pendred syndrome thyroid glands. 7 However, the goiter is not always present, and when it occurs usually does not manifest until the second decade of life. 7 Therefore, many EVA patients present with nonsyndromic hearing loss. 8 Serologic thyroid function tests are not sensitive for the early detection of Pendred syndrome, whereas the perchlorate discharge test is a sensitive method to detect the presymptomatic iodine organification defect in the thyroid glands of patients with Pendred syndrome glands. 7 However, SLC26A4 mutation testing and temporal bone imaging have essentially replaced the perchlorate discharge test for the diagnosis of Pendred syndrome. EVA is now recognized to be the most penetrant manifestation of SLC26A4 mutations. 9 Approximately 25% of North American-European Caucasian patients with EVA have two detectable mutant SLC26A4 alleles (termed M2), as expected for an autosomal recessive trait. [10] [11] [12] Another 25% of patients have only one detectable mutant SLC26A4 allele (termed M1), which is an incompletely diagnostic result. Cosegregation of SLC26A4-linked markers with EVA in M1 families suggests that undetected SLC26A4 mutations underlie the indistinguishable familial recurrence risk observed in M1 versus M2 families. 12 In contrast, the significantly lower recurrence risk and discordant segregation of SLC26A4-linked markers with EVA in M0 families suggests that other etiologies account for EVA in those patients. 12 To identify additional genes underlying EVA, we focused our study recruitment on families with multiple affected members. Among those families, we identified eight with atypical segregation of EVA (i.e., affected members in at least two sibships or generations in an extended family). We use the term segregation instead of inheritance because we could not be certain of a genetic etiology in all of the families. The SLC26A4 genotypes, phenotypes, and segregation patterns in our study families provide insight into possible etiologies of EVA and the foundation for investigations to identify novel genes for EVA.
MATERIALS AND METHODS
Subjects, methods, and their description are essentially as reported. 7, 10, 11, 13, 14 Our study was approved by the Combined Neuroscience Institutional Review Board, National Institutes of Health (NIH), Bethesda, Maryland. Written informed consent was obtained for all subjects. Self-reported race and ethnicity were classified according to our institutional review board reporting guidelines.
Subjects were evaluated at the NIH Clinical Center as previously described. 7, 10, 11, 13, 14 We relied upon records from outside healthcare providers for subjects who did not come to the NIH Clinical Center. All magnetic resonance imaging (MRI) or computed tomography (CT) scans were reviewed by the same neuroradiologist (J.A.B.) and otolaryngologist-head and neck surgeon (A.J.G.). We originally defined a vestibular aqueduct as enlarged if its diameter exceeded 1.5 mm at the midpoint between the posterior cranial fossa and the vestibule of the inner ear. 10 We subsequently revised our midpoint diameter criterion to >1.0 mm. Auditory evaluations included pure-tone and speech audiometry and CT and MRI of the temporal bones. 14 We defined normal hearing as air-conduction thresholds of 15 db HL for children (18 years old), and 25 db HL for adults, at the six octave test frequencies from 250 Hz to 8 kHz. For study subjects with known hearing loss, we considered their hearing loss to be inconsistent with EVA if they had an imaging study of the temporal bones that was negative for EVA, or if the loss had an onset during adulthood or was otherwise phenotypically distinguishable from EVA. Evaluation of the thyroid gland included: 1) measurement of peripheral venous blood levels of thyrotropin, thyroxine, free thyroxine, triiodothyronine, thyroglobulin, antithyroid peroxidase and antithyroglobulin antibodies, and thyroid-binding globulin; 2) ultrasonographic assessment of thyroid volume and texture; and, in some cases, 3) perchlorate discharge testing. 7 Ultrasonographic examinations were all analyzed by the same radiologist (THS), and perchlorate discharge studies were all performed according to our standard protocol. 7 The results of serologic, ultrasonographic, and perchlorate discharge studies were all interpreted according to our objective published criteria. 7 We identified eight families with at least two or more nonsibling members with EVA (Fig. 1) . We thus excluded families in which EVA was present only in a single sibship. We included families in which there was EVA present in a proband and parent (388, 442), grandparent (151), or great aunt (414), as well as families with more complex patterns of segregation. We included family 443 because three siblings had EVA, and the father had bilateral sensorineural hearing loss with bilateral cochlear modiolar hypoplasia, thought by some authors to be a forme fruste of ears with EVA. 15 The race of the eight families was white/Caucasian, and ethnicity was non-Hispanic.
We extracted genomic DNA and sequenced the 21 exons and flanking intronic regions of SLC26A4. 10, 11, 13 We performed haplotype analyses of SLC26A4-linked short tandem repeat markers (D7S496, D7S2459, and D7S2456) to track segregation of wild type alleles of SLC26A4. Zygosity of the twins (2107, 2108) in family 388 and parental relationships were determined by analysis of unlinked short tandem repeat markers spanning the rest of the genome. 12 The trans configuration of all compound heterozygous variants was confirmed by sequence analysis of parental DNA.
We classified the pathogenic potential of SLC26A4 variants according to American College of Medical Genetics guidelines. 16 To assess the pathogenic potential of p.V186F and p.N324Y, we generated complementary DNA expression constructs encoding wild type or mutant variants of SLC26A4 fused at its C-terminus to green fluorescent protein, transfected COS-7 cells, and evaluated intracellular localization by confocal microscopy. 11, 13 We evaluated anion exchange activity of the p.V186F and p.N324Y variants, fused at their C-terminus to a polyhistidine tag, 11, 13 encoded by complementary RNA injected into Xenopus oocytes. Chlorine-36 ( 36 Cl 2 ) influx and efflux were measured and analyzed as reported previously.
11,13 SLC26A4 mutation c.2320-2A>G (IVS20-2A>G) was considered pathogenic due to its predicted effect on a consensus splice acceptor site.
RESULTS
Family 151 (Fig. 1A ) included a previously reported female proband (1387) with bilateral EVA and an indeterminate thyroid phenotype. 10 Phenotypes of all affected subjects are summarized in Table I . Her paternal grandparents (1437, 1438) were reported to have severe to profound deafness since childhood but were not available for temporal bone imaging. Her parents (1364, 1365) had normal hearing, and her father (1364) had a temporal bone CT scan with normal findings. The proband was compound heterozygous for the pathogenic p.G209V and p.Y530S mutations of SLC26A4. Assuming the paternal grandfather had bilateral EVA, the vertical segregation of EVA in family 151 can be explained by transmission of p.G209V through the paternal lineage.
Family 414 (Fig. 1B) included a male proband (2186) with bilateral EVA and a normal thyroid phenotype assessed by ultrasonography and serologic tests of thyroid function. He had normal-hearing parents (2184, 2185) and a 46-year old paternal great aunt (2173) with bilateral EVA and a normal thyroid phenotype assessed by ultrasonography. Her thyroid stimulating hormone (TSH) level, 4.21 mIU/L, was slightly elevated (normal range 5 0.40-4.00 mIU/L). A second sample was drawn, and the TSH level was within the normal range. The proband (2186) was compound heterozygous for the pathogenic variant p.G209V and the likely pathogenic variant p.F335L of SLC26A4. The paternal great aunt (2173) had no detectable SLC26A4 variants, indicating that EVA had different etiologies in these different family members.
Family 347 (Fig. 1C) included two maternally related sibships with three first cousins (1991, 1992, 2044 ) with bilateral EVA and normal thyroid phenotypes. Three of the parents (1993, 1994, 2043 ) had normal hearing. One father (2004) had a unilateral mild-tomoderate sensorineural hearing loss at 4,000 to 8,000 Hz with a notched audiometric configuration, consistent with his history of exposure to recreational music and fireworks. We were unable to obtain an MRI scan. The grandparents were reported to have age-appropriate normal hearing, and this was confirmed by pure-tone audiometry in the grandfather. Subjects 1991, 1992, and 2044 had no detectable SLC26A4 mutations. Haplotype analyses of SLC26A4-linked short tandem repeat markers in 1991, 1992, 1993, and 1994 indicated that 1991 and 1992 inherited different SLC26A4 alleles from their parents, suggesting that their EVA may have been caused by X-linked or autosomal recessive alleles at another locus. The etiology of EVA in their first cousin (2044) remained unclear.
The female proband (1904) of family 317 (Fig. 1D ) had bilateral EVA and an indeterminate thyroid phenotype. Her parents (1906, 1907) , maternal grandparents Hearing loss consistent with EVA but not confirmed by radiologic imaging is indicated by gray symbols. Hearing loss that is known or suspected, based upon clinical presentation, to be unassociated with EVA is indicated by striped symbols. SLC26A4 genotypes are shown below the subject identification number. N324Y is shown for family 388 (E), although it is considered to be a benign variant. (1908, 1909) , and two maternal uncles all had severe-toprofound hearing loss. One uncle (2249) had bilateral EVA and a goiter. The other uncle was not available for temporal bone imaging or thyroid evaluations. A brother (1905) with normal hearing at 8 years of age ( Fig. 2A) was unavailable for temporal bone imaging or follow-up audiologic evaluation. There were six pathogenic SLC26A4 variants segregating in the family: the pathogenic mutations c.1151A>G (p.E384G), c.1246A>C (p.T416P), c.100111G>A (IVS811G>A), and c.1588T>C (p.Y530H), 11 the missense variant c.556G>T (p.V186F), and the splice site variant c.2320-2A>G (IVS20-2A>G). The prevalence of p.E384G, p.T416P. and IVS811G>A 11 among European Americans was 0.0349%, 0.0116%, and 0.0581%, respectively, as compiled in the Exome Variant Server accessed June 19, 2014 (http://evs.gs.washington. edu/EVS/). The p.V186F, p.Y530H, and IVS20-2A>G variants were not annotated in the Exome Variant Server, indicating that they are very rare. There were no GJB2 mutations detected in the participating family members. The mutant allele product SLC26A4 V186F failed to traffic to the plasma membrane of COS-7 cells (Fig. 3) . Furthermore, the mutant exhibited minimal or undetectable anion transport activity in Xenopus oocytes as measured by either unidirectional 36 Cl 2 influx (Fig. 4) Figure 1 in the online version of this article), indicating that this mutation is pathogenic.
We conclude that IVS20-2A>G is also pathogenic based upon its predicted disruption of the canonical splice acceptor site sequence. The proband 1904 was compound heterozygous for p.V186F and IVS20-2A>G. Her mother (1906), father (1907), maternal grandmother (1908), maternal grandfather (1909), and maternal uncle (2249) were also compound heterozygous for pathogenic mutations of SLC26A4, and were thus likely to have had EVA even though it was not documented. The proband's normal-hearing brother (1905) shared the same compound heterozygous mutant genotype, but we lacked sufficient clinical data to distinguish conclusively between nonpenetrance and presymptomatic EVA. We conclude that the vertical transmission of hearing loss, and documented or presumed EVA, in a pseudodominant pattern resulted from segregation of SLC26A4 mutations in family 317. Pseudodominant inheritance refers to the appearance of a dominant mode of inheritance when, in reality, the phenotype is associated with inheritance of two autosomal recessive alleles.
Family 388 (Fig. 1E ) comprised a mother (2106) and her monozygotic twin sons (2107, 2108), all with bilateral EVA. Subject 2106 had a normal-sized thyroid gland with a 3.8 3 5.4 3 5.1 mm solid nodule. Subjects 2107 and 2108 had normal-sized thyroid glands with a small cyst and a probable collapsed cyst, respectively. All three subjects had normal thyroid function and normal perchlorate discharge test results. The maternal grandmother had hearing loss detected in the fifth decade of life and required a cochlear implant in the eight decade. CT of her temporal bones was interpreted as negative for EVA. The scan was not available for our review. A maternal uncle was reported to have progressive hearing loss since the age of 10 years. He currently uses bilateral hearing aids, but no imaging studies or other results were available. The mother and sons (2106, 2107, 2108) were all heterozygous for c.970A>T (p.N324Y), which we previously reported as nonpathogenic. 13 The allele frequencies calculated from Exome Variant Server data (http://evs.gs.washington.edu/EVS/; accessed April10, 2015) were 0.05% among European Americans and 2.7% among African Americans. The variant allele product SLC26A4 N324Y trafficked to the plasma membrane of COS-7 cells in a pattern similar to that of wild type SLC26A4 (Fig. 3) . Moreover, SLC26A4
N324Y exhibited normal anion transport activity as measured in Xenopus oocytes by 36 Cl 2 influx (Fig. 4) Figure 2 in the online version of this article). These data strongly suggest that the p.N324Y mutation is benign. The segregation of EVA in family 388 may reflect inheritance of a mutant allele at another locus. Alternatively, EVA in twin offspring (2107, 2108) may reflect our previous observation of a potential causal association of twinning with EVA. 12 Thus, it is possible that the etiology of EVA differs between the mother and sons in family 388.
The affected members of family 442 (Fig. 1F) were a mother (2238) and son (2240) with bilateral EVA.
Their thyroid function testing and ultrasonography results were normal. They had no detectable SLC26A4 mutations and the results of outside OtoChip testing for hearing loss and Usher syndrome were negative for diagnostic variants in known hearing loss genes. The segregation of EVA in family 442 may reflect dominant, pseudodominant, or X-linked inheritance at another locus, different etiologies in the mother and son, or a combination of these possibilities.
The three affected male offspring (2246, 2247, 2248) of family 443 (Fig. 1G) all had bilateral sensorineural hearing loss. The siblings 2246 and 2248 had bilateral EVA. Sibling 2247 had not had temporal bone imaging. Their mother (2245) had normal hearing, but their father (2244) had bilateral mild-to-moderate sensorineural hearing loss (Fig. 2B) . MRI of his temporal bones revealed bilateral hypoplasia of the cochlear modiolus but no EVA (Fig. 5) . Because modiolar hypoplasia has been suggested to be a forme fruste of EVA, 15 the father (2244) could be considered to have the same phenotype as his sons, albeit with reduced severity. Hearing was reported to be normal for members of the extended family. There were no SLC26A4 mutations detected in 2244, 2246, 2247, or 2248. The segregation of EVA in family 443 may reflect semi-dominant or pseudodominant inheritance at another locus or different etiologies in the father and sons.
Family 372 (Fig. 1H ) segregated EVA in a complex pattern. The proband (2060) had bilateral EVA. Her father (2058) had unilateral EVA, whereas her mother (2059) and a maternal uncle (2061) had bilateral EVA. There were no reports of hearing loss or EVA among other members of the extended family. A 2-year-old male sibling (2225) without documented hearing loss was reported to have had a single episode of unexplained, sudden-onset ataxia requiring hospitalization, with a reportedly normal MRI study of the temporal bones at another facility. He was not available for evaluation at the NIH Clinical Center. We detected no SLC26A4 mutations in subjects 2058, 2059, 2060, 2061, or 2225. The segregation of EVA in the mother (2059) and maternal uncle (2061) are consistent with autosomal recessive or X-linked inheritance at another locus. If EVA in the father (2058) and mother (2059) was caused by mutant alleles at the same locus, the segregation of EVA in the proband (2060) would reflect pseudodominant or dominant inheritance at that locus. A shared etiology remained possible, because the parents shared remote ethnoreligious ancestry. However, we cannot rule out different etiologies in different members of the family. 17 
DISCUSSION
We have ascertained and described eight families, each with EVA in at least two members who were not related as siblings. In our experience and in the literature, occurrence of EVA in at least two sibships of an extended family is rare. In some cases, this represented multiple etiologies within the same family, as we showed for family 414. Intrafamilial etiologic heterogeneity was also a possibility in five of the other families in our study. In two families, 151 and 317, the vertical segregation of EVA was the result of pseudodominant inheritance of recessive mutations of SLC26A4. This pattern of inheritance of SLC26A4 mutations and Pendred syndrome has been previously reported. [18] [19] [20] In general, pseudodominant inheritance of recessive hearing loss alleles is rare in outbred populations due to nonassortative (random) mating and the low prevalence of mutant alleles. Pseudodominant inheritance of hearing loss in the deaf population can result from assortative mating and a higher prevalence of hearing loss alleles. 21 It is not surprising to observe pseudodominant inheritance of recessive mutations of SLC26A4, because they appear to be the second most common known cause of genetic deafness across the globe. 18 Five study families (347, 372, 388, 442, and 443) did not segregate detectable SLC26A4 mutations. Furthermore, EVA did not cosegregate with SLC26A4-linked markers, suggesting that EVA was not caused by undetected mutations of SLC26A4. These M0 families may segregate mutations of another gene(s) at another locus or loci. The noncomplementary mating in family 372 raises the possibility of a major gene or mutation accounting for EVA in affected members of these families and others. The low recurrence risk of EVA in M0 families indicates that mutations of another gene or other genes are a rare cause of EVA, have low penetrance, or both. 12 Variants of FOXI1, KCNJ10, and the 5 0 -untranslated region of SLC26A4 have been proposed by Yang et al. to cause EVA, 22, 23 but those hypotheses have not been supported in other studies to date. [24] [25] [26] [27] It remains possible that the low recurrence risk of EVA in M0 families reflects a nongenetic etiology. Congenital cytomegalovirus infection is a common cause of childhood hearing loss, but it is not a major cause of EVA. 28 There is also an association of twinning with EVA, 12 but twinning cannot account for EVA in most of the families in this study.
The primary weakness of our study was incomplete clinical data for some of the members of the study families. For families 151, 317 and 414, the lack of phenotypic data did not affect the interpretation of segregation. Additional clinical data could potentially clarify the phenotype in some members of the five M0 families for whom the underlying etiology remains unknown. However, it seems unlikely the additional data would affect our interpretation of the segregation pattern.
Although the etiology of M0 EVA remains unknown, it deserves further investigation, because approximately 50% of all EVA probands have no detectable SLC26A4 mutations. Identifying other etiologies of EVA will facilitate counseling of patients and families, our understanding of the etiology of hearing loss in EVA, as well as stratification of patients for potential interventions to prevent, reduce, or reverse the hearing loss associated with EVA.
CONCLUSION
Segregation of EVA with hearing loss can demonstrate a variety of atypical patterns in families. SLC26A4 mutation testing is a critical diagnostic test in families with atypical patterns of segregation of EVA. Pseudodominant inheritance of SLC26A4 mutations can account for atypical segregation of EVA in families with intermarriage among deaf individuals. The etiologic basis of atypical segregation of EVA in families without SLC26A4 mutations remains unknown. These families may allow discovery of novel genes and mechanisms for EVA.
